IP Library Granted Patent US 7,749,506
Granted Patent B2
US 7,749,506 · App. 11/737,227 · Granted Jul 6, 2010

Proteins derived from white spot syndrome virus and uses thereof

Assignee: Intervet International B.V.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,749,506
App. No.
11/737,227
Granted
Jul 6, 2010
Kind
B2
Abstract

Embodiments of the present invention generally relate to proteins derived from white spot syndrome virus, nucleic acid sequences encoding them, and their use in the manufacture of a vaccine for prophylaxis and/or treatment of white spot syndrome in crustaceans.

Claims (4)

1. An isolated and purified white spot syndrome envelope protein having the amino acid sequence depicted in SEQ ID NO. 4.

2. A pharmaceutical composition for treatment of white spot syndrome in crustaceans comprising an immunogenically effective amount of an envelope protein set forth as SEQ ID NO. 4 and a pharmaceutically acceptable carrier.

3. A method for immunizing crustaceans against White Spot Syndrome, wherein the method comprises administering an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an envelope protein comprising the amino acid sequence depicted in SEQ ID NO. 4.

4. The method according to claim 3 , wherein the pharmaceutical composition further comprises at least one additional white spot syndrome virus protein.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 13, 2007
From: AKZO NOBEL N.V.
To: INTERVET INTERNATIONAL B.V.
Reel/Frame 019556/0098 →
Priority Claims (2)
EP 99202545 · Aug 3, 1999 · regional
EP 00200248 · Jan 24, 2000 · regional
Continuity (2)
Continuation 1004874900
Related Publication 20090068212A1 · Mar 12, 2009